Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Exclusion Criteria

• •Symptomatic, untreated, or actively progressing CNS metastases
• •Significant cardiovascular disease
• •Adverse reactions of Grade ≥1 that are still continuing due to previous treatments. Exceptions are those of hair loss or which researchers take it as exception
• •Major surgery was performed within 3 weeks of the first course of trial treatment (except for minor outpatient surgery, such as placement of vascular access)
• •Pregnancy or breastfeeding, or intention of becoming pregnant during the study
• •Other malignancies within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma
• •Inability to swallow, chronic diarrhea and intestinal obstruction, there are multiple factors that affect the use and absorption of drugs
• •Presence of third-space fluid accumulation that cannot be controlled by drainage or other methods (such as excessive pleural fluid and ascites)
• •Participated in clinical trials of other antitumor drugs within 4 weeks before first taking the investigational drug
• •Long-term unhealing wound or incomplete healing of fracture
• •Patients with known active HBV or HCV infection or hepatitis B DNA≥500, or chronic phase with abnormal liver function
• •Allergic constitution, or known allergic history of the drug components of this trial; Or allergic to other monoclonal antibodies
• •Patients with a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding within the past 6 months, such as esophageal varicose veins with bleeding risk, locally active ulcer lesions, stool occult blood ≥ (++), were not allowed to enter the group; If there is occult blood in the stool (+), gastroscopy is required
• •Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 28 days before participating in this trial
• •Urine protein ≥2+ and 24h urine protein quantitative \> 1.0 g
• •Patients suffering from hypertension and unable to reach the normal range after antihypertensive drug treatment (systolic blood pressure \>140mmHg, diastolic blood pressure \>90mmHg)